Please login to the form below

Not currently logged in

P&G signs bioinformatics deal to speed new product research

Will use Eagle Genomics' software platform Eaglecore


Procter & Gamble (P&G) has signed a four-year agreement to use bioinformatics software to help boost the development of new products including pharmaceuticals, consumer goods and biofuels.

The firm will use Eagle Genomics' secure, cloud-based, Eaglecore platform to organise existing data and integrate existing data with new analysis from across the company.

Dr Abel Ureta-Vidal, CEO of Eagle, said: “Eaglecore is an extremely powerful platform and will have a major impact on P&G's approach to their current research projects.

“By using out platform, P&G will be able to better reference, manage and use all of their data to develop new insights and products, saving both time and development costs.”

The deal will see P&G take a four-year license for an undisclosed sum, which will include additional data curation services. The agreement follows a long partnership between the two companies involving Eagle's consultancy arm, which has been used to support past research.

Eagle, which allows large-scale genomics data and data generation technologies to be applied to world issues, was earlier this year awarded funding from the UK's Department of Health to develop proposals to help to with treating rare diseases and cancer.

Article by
Kirstie Pickering

12th December 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...